A tablet which is easy to ingest, contains 500 mg of levofloxacin, has a mass of 570 to 700 mg, a projected area of 90 to 125 mm2 on a plan view and a hardness of 30 to 300 N, and can be divided easily.

PROBLEM TO BE SOLVED: To provide levofloxacin-containing tablets excellent in degradability and suspendibility in water. SOLUTION: The tablets contain components of (A) levofloxacin and (B) a polyvinyl-based binder preferably polyvinylpyrrolidone (PVP) or polyvinyl alcohol (PVA). COPYRIGHT: (C)2008JPO&INPIT

Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infe...

PROBLEM TO BE SOLVED: To provide an anti-cancer agent for prevention or treatment of carcinoma, sarcoma or hematopoietic cancer.

PROBLEM TO BE SOLVED: To provide a tablet containing an angiotensin II receptor antagonist and a calcium antagonist useful for treatment of hypertension and having an improved elution property. SOLUTION: The tablet is a nucleated tablet comprising granules containing olmesartan medoxomil as an active ingredient and granules containing amlodipine besilate or azelnidipine as another active ingredient wherein these granules are compounded in separate layers and the tablet further contains hydroxyp...

The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione...

Disclosed herein is a method of producing prasugrel hydrochloride (compound of formula (Ia)), comprising the steps of: i) chlorinating a compound represented by formula (III), by adding a chlorinating agent optionally dropwise thereto in a solvent

PROBLEM TO BE SOLVED: To provide a mixture preparation in which stability and elution characteristics of major medicines olmesartan medoxomil and azelnidipine are excellent. SOLUTION: The solid preparation contains olmesartan medoxomil and azelnidipine separately in a form not contacting to each other. The solid preparation is a multilayered pill in which the amount of azelnidipine mixed into the layer containing olmesartan medoxomil is controlled to at most 4.5 mass% of the amount of olmesarta...